global
preval
allerg
diseas
continu
rise
recent
decad
despit
evid
trend
toward
plateau
asthma
preval
develop
countri
epidemiolog
find
suggest
increas
may
attribut
reduc
childhood
exposur
infect
result
antibiot
vaccin
improv
sanit
thelper
th
regulatori
treg
cell
play
vital
role
regul
adapt
immun
respons
infect
hygien
hypothesi
propos
reduct
treglik
respons
result
lack
exposur
infect
childhood
may
polaris
immun
system
toward
allergenreact
respons
genet
suscept
individu
recent
studi
report
amish
farm
commun
expos
microbi
product
lipopolysaccharid
lp
demonstr
increas
innat
immun
respons
associ
low
overal
incid
asthma
allergi
allerg
asthma
chronic
inflammatori
disord
airway
characteris
eosinophil
infiltr
airway
hyperrespons
ahr
excess
airway
mucu
product
cell
respond
environment
antigen
secret
rang
cytokin
includ
interleukin
il
respons
suppress
treg
cell
secret
antiinflammatori
cytokin
type
ii
interferon
gamma
secret
cell
tolllik
receptor
tlr
play
key
role
within
innat
immun
system
recognis
pathogenassoci
molecular
pattern
pamp
via
leucinerich
pattern
recognit
receptor
prr
domain
primarili
express
plasmacytoid
dendrit
cell
detect
infect
singlestrand
ribonucl
acid
ssrna
virus
includ
influenza
coronaviru
rhinoviru
activ
trigger
innat
immun
respons
signal
cascad
involv
recruit
myeloid
differenti
primari
respons
receptorassoci
kinas
receptorassoci
kinas
tnf
receptorassoci
factor
interferon
regulatori
factor
phosphoryl
subsequ
upregul
product
type
interferon
ifn
help
regul
activ
immun
system
agonist
potenti
new
treatment
option
allerg
asthma
reduc
respons
allergen
agonist
shown
upregul
respons
downregul
respons
allergen
murin
model
allerg
chronic
asthma
varieti
complex
mechan
activ
nuclear
factor
pathway
transcript
factor
increas
product
cytokin
includ
chemokin
type
ifn
also
appear
depend
type
ii
novel
agonist
develop
treatment
asthma
allerg
rhiniti
order
restrict
effect
drug
site
administr
minimis
potenti
side
effect
associ
system
cytokin
product
design
antedrug
metabol
labil
ester
topic
activ
rapidli
hydrolys
butyrylcholinesteras
much
less
activ
metabolit
upon
entri
circul
studi
administ
intranas
minimis
risk
local
inflammatori
effect
lung
reduc
risk
system
activ
earli
murin
studi
show
localis
inflammatori
effect
lung
high
dose
partial
resolut
cessat
complet
resolut
lower
dose
studi
demonstr
efficaci
inhal
intranas
administr
support
evid
immunolog
linkag
upper
lower
respiratori
tract
man
unit
airway
hypothesi
clinic
develop
becam
focus
intranas
administr
shown
inhibit
allergen
respons
patient
allerg
rhiniti
aim
studi
examin
efficaci
safeti
toler
intranas
administ
onceweekli
week
patient
physiciandiagnos
mild
allerg
asthma
subsequ
challeng
inhal
allergen
studi
enrol
male
femal
non
exsmok
age
year
global
initi
asthma
gina
defin
mildtomoder
asthma
month
durat
posit
skin
prick
test
grass
hous
dust
mite
cat
dander
within
previou
month
clinicaltrialsgov
identifi
studi
conduct
initi
safeti
toler
pilot
studi
n
placebo
n
initi
main
studi
inclus
main
part
studi
patient
demonstr
forc
expiratori
volum
predict
normal
earli
asthmat
respons
ear
correspond
decreas
within
h
late
asthmat
respons
lar
correspond
decreas
h
postallergen
challeng
consecut
occas
methacholin
provoc
concentr
lead
reduct
mgml
inhal
allergen
use
one
patient
shown
posit
respons
skin
prick
test
patient
exclus
criteria
symptomat
allerg
rhiniti
symptomat
allerg
asthma
exclud
previou
treatment
inhal
corticosteroid
longact
week
first
studi
visit
use
antihistamin
within
week
system
corticosteroid
within
week
respiratori
tract
infect
within
week
asthma
exacerb
within
week
visit
use
shortact
permit
except
h
prior
spirometri
studi
visit
inhal
corticosteroid
ic
stop
week
prior
first
methacholin
challeng
visit
fig
studi
approv
wandsworth
research
ethic
committe
london
conduct
accord
declar
helsinki
complianc
intern
confer
harmonisationgood
clinic
practic
written
inform
consent
obtain
patient
doubleblind
placebocontrol
randomis
parallelgroup
studi
patient
mildtomoder
allerg
asthma
conduct
two
centr
uk
fig
addit
file
figur
studi
compris
initi
screen
period
week
prior
randomis
methacholin
challeng
allergen
challeng
titrat
perform
methacholin
challeng
perform
accord
local
standard
oper
procedur
increas
doubl
concentr
methacholin
start
mgml
mgml
screen
period
mgml
treatment
period
administ
fall
post
salin
valu
achiev
fivebreath
dosimet
five
inhal
methacholin
administ
method
use
salbutamol
administ
revers
bronchoconstrict
conclus
test
necessari
particip
measur
min
postbronchodil
administr
everi
min
return
valu
within
baselin
provoc
concentr
methacholin
caus
fall
mgml
patient
exclud
visit
allergenchalleng
titrat
procedur
perform
screen
period
conduct
follow
method
boulet
et
al
establish
individu
toler
repeat
yet
symptominduc
dose
inhal
allergen
increas
dose
grass
pollen
hous
dust
mite
cat
allergen
alkabello
administ
min
observ
period
dose
ear
observ
follow
allergen
challeng
patient
remain
clinic
h
overnight
safeti
concern
judg
investig
cumul
dose
allergen
produc
desir
effect
fall
least
patient
use
patient
singl
bolu
dose
two
subsequ
challeng
week
week
last
dose
treatment
least
week
allergen
challeng
patient
enter
main
treatment
period
randomis
intranas
onceweekli
placebo
week
key
efficaci
assess
perform
week
last
dose
studi
drug
match
placebo
administ
nasal
spray
solut
studi
product
contain
buffer
steril
salin
solut
also
use
match
placebo
product
provid
glass
vial
fit
pump
spray
devic
deliv
per
actuat
administ
dose
singl
spray
nostril
administ
clinic
visit
total
dose
administ
period
dose
schedul
use
studi
select
basi
phase
iii
clinic
data
studi
drug
administr
perform
clinic
separ
room
equip
fume
chamber
individu
nasal
spray
vial
prime
administr
advers
effect
level
noael
lung
exposur
avail
time
studi
investig
studi
nurs
instruct
patient
exhal
oral
resist
close
connect
lung
nasal
airway
manoeuvr
investig
studi
nurs
administ
spray
ensur
deliveri
nasal
mucosa
avoid
administr
lung
plasma
concentr
repres
sum
concentr
main
acid
metabolit
shown
addit
file
figur
primari
outcom
variabl
area
curv
auc
base
averag
mean
fall
predos
valu
h
interv
post
allergen
assess
lar
week
posttreat
serial
measur
perform
everi
min
data
allergen
challeng
summar
term
two
mean
valu
comput
area
curv
trapezoid
rule
divid
observ
time
data
analys
litr
percent
chang
mean
valu
zero
valu
first
measur
visit
measur
prior
allergen
challeng
addit
allergen
challeng
week
posttreat
use
assess
durat
efficaci
secondari
outcom
includ
ear
measur
averag
fall
h
postallergen
challeng
methacholin
challeng
provoc
concentr
methacholin
caus
fall
use
assess
allergeninduc
ahr
analys
biomark
includ
blood
sputum
cytokin
cell
count
carri
explor
mechan
action
baselin
biomark
includ
blood
sputum
eosinophil
assess
visit
treatment
safeti
toler
assess
advers
event
ae
vital
signselectrocardiograph
paramet
sampl
assay
cytokin
multiplex
use
msd
proinflammatori
ii
mesoscal
discoveri
plate
sputum
cell
cultur
supernat
sputum
sampl
induc
first
studi
visit
allergen
challeng
third
studi
visit
allergen
challeng
provid
baselin
biomark
measur
includ
eosinophil
fig
sputum
induct
repeat
visit
visit
last
dose
allergen
challeng
visit
last
dose
follow
allergen
challeng
provid
inform
durat
observ
effect
studi
drug
week
week
postdos
sputum
induct
perform
min
administr
salbutamol
hyperton
salin
inhal
min
three
cycl
expector
primari
outcom
evalu
use
analysi
varianc
anova
outcom
variabl
treatment
factor
pretreat
visit
lar
covari
result
present
ratio
mean
secondari
outcom
variabl
aucbas
ear
analys
way
aucbas
lar
secondari
outcom
variabl
biomark
sputum
methacholin
measur
prior
allergen
challeng
post
challeng
visit
treatment
week
treatment
period
addit
file
figur
secondari
measur
analys
use
anova
methacholin
data
estim
loglinear
interpol
exp
lnci
ri
safeti
toler
data
describ
use
descript
statist
sampl
size
estim
found
subject
per
group
would
provid
power
detect
rel
differ
lar
follow
allergen
challeng
patient
receiv
least
dose
randomis
treatment
postdos
data
avail
includ
efficaci
safeti
popul
full
analysi
set
total
patient
randomis
patient
complet
studi
group
placebo
group
addit
file
figur
baselin
demograph
characterist
patient
similar
randomis
placebo
group
although
sputum
eosinophil
level
similar
two
group
group
slightli
lower
baselin
eosinophil
count
tabl
total
patient
discontinu
studi
prematur
mainli
due
advers
event
tabl
efficaci
analysi
set
consist
patient
alloc
treatment
lar
data
avail
baselin
postallergen
averag
lar
fall
sd
l
group
l
placebo
group
week
last
dose
treatment
significantli
reduc
averag
lar
fall
compar
placebo
p
fig
effect
sustain
week
last
dose
p
fig
show
trend
toward
decreas
maxim
lar
fall
versu
placebo
week
dose
reduct
reach
statist
signific
decreas
vs
placebo
p
post
hoc
subanalysi
conduct
examin
postallergen
lar
averag
fall
accord
baselin
blood
eosinophil
level
record
visit
higher
proport
patient
group
eosinophil
level
n
vs
placebo
n
reflect
slight
differ
baselin
level
vs
placebo
week
last
dose
averag
lar
fall
post
allergen
challeng
significantli
reduc
compar
placebo
patient
baselin
eosinophil
level
reduct
p
cut
valu
eosinophil
base
previou
public
effect
maintain
week
post
dose
fig
signific
reduct
lar
observ
patient
baselin
blood
eosinophil
level
reduct
p
week
week
treatment
averag
ear
fall
numer
reduc
versu
placebo
week
last
dose
reach
statist
signific
p
fig
effect
demonstr
repeat
allergen
challeng
week
posttreat
fig
attenu
methacholineinduc
ahr
compar
placebo
allergen
challeng
perform
week
last
dose
treatment
ratio
ci
p
effect
observ
preallergen
methacholin
challeng
week
last
dose
effect
ahr
week
last
dose
signific
chang
baselin
visit
plasma
cytokin
sputum
cytokin
sputum
eosinophil
level
either
placebo
group
week
last
dose
signific
differ
group
trend
toward
reduct
sputum
cytokin
sputum
eosinophil
observ
week
last
dose
compar
placebo
prior
allergen
challeng
fig
p
p
p
respect
addit
file
tabl
figur
expect
robust
cytokin
respons
postallergen
challeng
blood
sputum
sampl
howev
signific
chang
baselin
respons
week
cessat
dose
placebo
addit
appear
differ
gene
express
chang
local
system
group
placebo
group
week
postdos
allergen
challeng
allergen
recal
assay
patient
provid
sampl
expect
allergeninduc
increas
cytokin
observ
pbmc
prepar
predos
blood
sampl
placebo
group
signific
increas
either
indic
good
biomark
respons
hous
dust
mitesensit
individu
signific
chang
respons
observ
week
postdos
either
placebo
gener
well
toler
influenzalik
symptom
report
frequent
treatment
period
compar
placebo
tabl
death
occur
studi
seriou
ae
report
bacteri
tonsil
occur
placebo
group
ae
lead
discontinu
studi
treatment
dae
occur
placebo
recipi
one
patient
treatment
group
discontinu
due
asthma
relat
event
patient
treatment
group
discontinu
due
rais
transaminas
group
dae
includ
pyrexia
back
pain
loss
conscious
femal
age
year
arthralgia
somnol
headach
male
vast
major
ae
mild
moder
intens
headach
nasal
dryness
arthralgia
pyrexia
commonli
report
ae
relat
treatment
tabl
nasal
symptom
includ
epistaxi
rhinorrhoea
nasal
congestionobstruct
sneez
nasal
dryness
nasal
ulcer
equal
distribut
treatment
clinic
relev
chang
vital
signselectrocardiograph
paramet
observ
studi
patient
allerg
asthma
demonstr
intranas
administr
agonist
attenu
averag
postallergen
lar
fall
prevent
increas
ahr
follow
allergen
challeng
week
last
dose
gener
well
toler
current
avail
asthma
therapi
although
effect
major
patient
provid
adequ
asthma
control
substanti
number
patient
requir
chronic
dose
potenti
side
effect
particularli
higher
dose
agonist
potenti
new
treatment
option
allerg
asthma
stimul
effector
cell
therebi
attenu
allergenspecif
cell
potenti
drawback
approach
system
induct
proinflammatori
cytokin
result
influenzatyp
side
effect
overcom
problem
antedrug
approach
employ
metabol
labil
ester
plasma
halflif
min
rapidli
convert
weakli
activ
metabolit
plasma
min
hypothesi
would
minim
system
exposur
limit
ifn
immun
activ
due
brief
halflif
result
reduc
incid
side
effect
studi
drug
administ
local
nose
avoid
inhal
lung
therapeut
effect
observ
lung
minim
system
exposur
preclin
studi
murin
model
demonstr
intranas
administr
confer
sustain
protect
allergen
challeng
allergen
challeng
model
man
import
predictor
subsequ
efficaci
treatment
asthma
inhal
steroid
shown
inhibit
lar
singl
dose
multipl
dose
sever
week
requir
demonstr
inhibit
ear
lar
gauvreau
et
al
report
lack
effect
allergen
challeng
novel
immunomodulatori
agent
induc
ifn
gamma
via
receptor
stimul
howev
mechan
restrict
rang
stimulatori
effect
immun
cell
man
contrast
agonist
first
intranas
administ
immunomodulatori
compound
shown
attenu
allergeninduc
lar
ahr
week
treatment
effect
observ
week
final
dose
studi
need
evalu
potenti
durat
effect
differ
dose
frequenc
durat
explor
may
possibl
reset
immun
system
reduc
minimis
allerg
respons
treatment
approach
subgroup
analysi
reveal
effect
lar
patient
pronounc
higher
plasma
eosinophil
group
x
greater
report
outcom
full
studi
popul
result
highlight
import
identifi
differ
phenotyp
asthma
result
also
consist
report
reduc
allergen
respons
day
final
dose
patient
allerg
rhiniti
administr
directli
lung
previous
shown
inhibit
eosinophilia
level
week
posttreat
follow
ovalbumin
challeng
brown
norway
rat
current
studi
signific
chang
observ
sputum
cytokin
eosinophil
count
intranas
treatment
week
postdos
either
allergen
challeng
although
trend
toward
reduct
cytokin
sputum
eosinophil
prior
allergen
challeng
week
last
dose
reach
statist
signific
howev
rang
sputum
cell
data
n
per
group
total
number
subject
n
placebo
n
opinion
reduc
number
sputum
sampl
respect
treatment
group
low
demonstr
statist
differ
group
observ
trend
reduc
reduc
eosinophil
togeth
preclin
result
suggest
agonist
may
suppress
immun
state
asthmat
subject
challeng
allergen
chang
ifnregul
gene
express
week
postdos
current
studi
keep
previou
clinic
studi
lack
effect
pbmc
respons
allergen
recal
experi
suggest
provid
protect
allerg
inflamm
induc
hous
dust
mite
allergen
week
postdos
primari
outcom
variabl
allergen
challeng
test
area
curv
auc
power
calcul
endpoint
perform
sampl
size
base
formal
power
calcul
instead
practic
approach
use
obtain
mani
sampl
feasibl
within
studi
absenc
signific
effect
exploratori
biomark
studi
week
postdos
indic
unwant
induct
system
cytokin
administr
design
studi
assess
upregul
respons
assum
inhibit
lar
observ
due
mechan
cellular
molecular
mechan
brief
intranas
exposur
agonist
produc
longterm
immun
effect
lung
remain
specul
although
unit
airway
hypothesi
may
involv
precis
mechan
agonist
abrog
lar
allerg
asthmat
also
remain
elucid
possibl
antigen
present
cell
dendrit
cell
certain
macrophag
eg
subtyp
may
traffic
lymph
node
exogen
exposur
nose
altern
innat
lymphoid
cell
may
involv
three
subtyp
ilc
may
involv
gener
respons
activ
epithelialderiv
cytokin
thymic
stromal
lymphopoietin
tslp
wherea
type
cell
may
stimul
agonist
revers
trend
toward
asthma
phenotyp
releas
tslp
appear
import
common
pathway
airway
epithelium
inflammatori
cascad
count
cell
nk
cell
found
low
patient
sever
asthma
activ
induc
transcript
induct
innat
immun
respons
typic
product
proinflammatori
cytokin
upregul
respons
may
alter
versu
immun
state
suscept
asthma
subject
result
abrog
allerg
respons
induc
allergen
nevertheless
studi
effect
whilst
persist
week
beyond
end
dose
sustain
rel
longer
period
seen
rodent
model
direct
stimul
lung
may
need
effect
sustain
chang
immun
respons
remain
establish
whether
administr
directli
human
lung
might
induc
effect
equival
magnitud
durat
seen
rodent
model
inflammatori
diseas
administ
onceweekli
treatment
period
gener
well
toler
report
clinic
studi
symptom
possibl
link
activ
pathway
preval
administr
compar
placebo
gener
mild
intens
increas
nasal
side
effect
previous
report
treatment
notabl
dose
frequent
dose
present
studi
lower
dose
onceweekli
overal
incid
nasal
symptom
similar
activ
placebotr
group
incid
mucos
ulcer
limit
singl
individu
activ
treatment
group
conclud
intranas
attenu
allergeninduc
lar
prevent
allergeninduc
increas
ahr
patient
allerg
asthma
week
posttreat
administ
onceweekli
week
gener
well
toler
studi
demonstr
intranas
administr
agonist
amelior
allergeninduc
respons
lower
airway
carri
one
week
follow
cessat
dose
allergen
studi
conduct
challeng
dose
period
intrigu
find
signific
amelior
allergen
challeng
conduct
least
one
week
last
dose
time
detect
drug
level
accord
pharmacokinet
analysi
impli
agonist
immunomodulatori
effect
persist
known
pharmacokinet
action
drug
immunomodulatori
effect
detect
three
week
dose
final
allergen
challeng
albeit
effect
much
weaker
time
point
fail
reach
signific
